🇨🇿
Peptide Laws in Czech Republic
CZ · Europe · 23 peptides tracked
Grey AreaEnforcement: Lenient
Are Peptides Legal in Czech Republic?
The Czech Republic is among the most permissive EU countries for research peptides. SUKL oversees pharmaceutical regulation, but enforcement against personal-use research chemicals is minimal. Several vendors operate openly, and the country has a generally pragmatic approach to regulation. Semaglutide is available by prescription. If you're in the EU and looking for research peptides, Czechia is one of the easier places to access them.
4
Legal16
Grey Area3
PrescriptionCan You Buy Peptides in Czech Republic?
4 peptide(s) are legal to buy in Czech Republic, including GHK-Cu, NAD+, Glutathione, Vitamin B12. 3 peptide(s) require a valid prescription, including Tirzepatide, Semaglutide, CJC-1295. 16 peptide(s) fall into a legal grey area: Selank, MOTS-c, TB-500, Ipamorelin, Semax, and 11 more. These may be available for research purposes but their legality for personal use is ambiguous.
Traveling to Czech Republic with Peptides
When traveling to Czech Republic with peptides, the legality depends on each peptide's classification. Prescription peptides (Tirzepatide, Semaglutide, CJC-1295) typically require documentation such as a prescription or doctor's letter when crossing borders. Enforcement in Czech Republic is rated as "Lenient." Always declare pharmaceutical products at customs and carry documentation of any prescriptions.
New to peptides? Start with the basics on peptide.camp →
Need to source peptides for Czech Republic? Get verified wholesale quotes on peptide.broker →
Traveling to Czech Republic with peptides? TSA tips, packing guides & the peptide travel case on peptide.travel →
Peptide Regulations in Czech Republic
| Peptide | Status | Rx Required | Schedule | Detail | Source |
|---|---|---|---|---|---|
| Tirzepatide | Prescription | Yes | EMA Authorized (Rx) | EMA-authorized. Mounjaro. Prescription required. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| Selank | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Approved in Russia. Research-label available. Not on WADA prohibited list. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| MOTS-c | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| TB-500 | Grey Area | No | Not Scheduled / Unauthorized | Same permissive environment as BPC-157. Research vendors operate extensively. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| GHK-Cu | Legal | No | Cosmetic Ingredient | Legal cosmetic ingredient under EU Cosmetics Regulation 1223/2009. Topical forms sold freely. Injectable form unauthorized. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| Ipamorelin | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GHRP. WADA banned. Research-label available. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| Semaglutide | Prescription | Yes | EMA Authorized (Rx) | EMA-authorized. Ozempic/Wegovy. Prescription required. Massive counterfeit/compounded market. EMA warned of 'sharp rise in illegal medicines'. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| CJC-1295 | Prescription | Yes | Unauthorized Medicine | No EMA authorization. GHRH analog. WADA banned. Research-label available. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| Semax | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Approved in Russia. Research-label available. Not on WADA prohibited list. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| BPC-157 | Grey Area | No | Not Scheduled / Unauthorized | Home of Janoshik testing lab. Major research chemical hub. Most permissive enforcement in EU. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| NAD+ | Legal | No | Supplement / Novel Food | Supplements (NMN/NR) widely sold. IV infusions at clinics. NMN awaiting EFSA novel food assessment (Uthever 2025). As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| Retatrutide | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| AOD-9604 | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| Glutathione | Legal | No | Supplement | — | Unsourced |
| DSIP | Grey Area | No | Not Scheduled / Unauthorized | — | Unsourced |
| Epithalon | Grey Area | No | Not Scheduled / Unauthorized | — | Unsourced |
| KPV | Grey Area | No | Not Scheduled / Unauthorized | — | Unsourced |
| HGH | Grey Area | No | Unregistered | — | Unsourced |
| Liraglutide | Grey Area | No | Unregistered | — | Unsourced |
| Melanotan II | Grey Area | No | Not Scheduled / Unauthorized | — | Unsourced |
| MK-677 | Grey Area | No | Unregistered | — | Unsourced |
| Vitamin B12 | Legal | No | Supplement | — | Unsourced |
| PT-141 | Grey Area | No | Unregistered | — | Unsourced |
About the sources on this page
Entries marked Official cite a government regulator, legislation or an official gazette. Some entries currently carry no source at all.
We show these entries rather than hiding them, but they should not be relied on. Nothing on this site is legal advice. Verify against the national regulator before acting, and if you can point us at a better source please submit an update.
Data is researcher-verified but not legal advice. Always consult local regulations before purchasing, importing, or traveling with peptides. Last verified: 2026-02-28.